


EMERGING APPROACHES TO TACKLE NEGLECTED DISEASES

FROM MOLECULE TO END PRODUCT



Editors:
Prerna Sharma
Sumeet Gupta
Hitesh Malhotra
Bhawna Chopra
Sunil Sharma

Bentham Books

Emerging Approaches to Tackle Neglected Diseases: From Molecule to End Product

Edited by

Prerna Sharma

*Guru Gobind Singh College of Pharmacy
Yamunanagar, India*

Sumeet Gupta

*MM College of Pharmacy
MMU, Mullana, Haryana
India*

Hitesh Malhotra

*Guru Gobind Singh College of Pharmacy
Yamunanagar, India*

Bhawna Chopra

*Guru Gobind Singh College of Pharmacy
Yamunanagar, India*

&

Sunil Sharma

*Guru Jambheshwar University of Science and Technology
Hisar, India*

**Emerging Approaches to Tackle Neglected Diseases:
From Molecule to End Product**

Editors: Perna Sharma, Sumeet Gupta, Hitesh Malhotra,

Bhawna Chopra & Sunil Sharma

ISBN (Online): 978-981-5196-86-3

ISBN (Print): 978-981-5196-87-0

ISBN (Paperback): 978-981-5196-887

© 2024, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

First published in 2024.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

PREFACE	i
LIST OF CONTRIBUTORS	iii
CHAPTER 1 NEGLECTED TROPICAL DISEASES	1
<i>Garima Malik, Meenakshi Dhanawat and Kashish Wilson</i>	
1. INTRODUCTION	1
2. EPIDEMIOLOGY AND RISK FACTORS	3
2.1. Buruli Ulcer	4
2.2. Chikungunya	4
2.3. Chagas Disease	5
2.4. Dengue Fever	5
2.5. Human African Trypanosomiasis	5
2.6. Leishmaniasis	6
2.7. Lymphatic Filariasis	6
2.8. Soil-Transmitted Helminthiasis	7
2.9. Onchocerciasis	7
2.10. Scabies	8
2.11. Schistosomiasis	8
2.12. Trachoma	9
2.13. Rabies	9
2.14. Dracunculiasis (or Guinea Worm Disease)	9
2.15. Leprosy	10
3. RECOMMENDATIONS	10
CONCLUSION	11
REFERENCES	12
CHAPTER 2 STRATEGIES TO OVERCOME THE IMPACT OF NEGLECTED DISEASES ON THE WORLD	16
<i>Namratha MP, Pooja Mittal, Anjali Sharma and Vishnu Mittal</i>	
1. INTRODUCTION	16
2. IMPACT OF NDTs	18
2.1. To Defeat the Impact of NDTs on World's Health and Economy	18
2.1.1. <i>Mass Drug Administration (MDA)</i>	18
2.1.2. <i>Improved Sanitation and Hygiene</i>	18
2.1.3. <i>Vector Control</i>	19
2.1.4. <i>Vaccination Programs</i>	19
2.1.5. <i>Health Education and Community Engagement</i>	19
2.2. The Global Plan Focused on Four Main Pillars	20
2.2.1. <i>Preventive Chemotherapy</i>	20
2.2.2. <i>Innovative and Intensified Disease Management</i>	20
2.2.3. <i>Vector Control and Vector-borne Diseases</i>	21
2.2.4. <i>Water, Sanitation, and Hygiene (WASH)</i>	21
3. GLOBAL GOALS	23
3.1. WHO-2012:Implementation of Roadmap	23
3.2. London Declaration on the Neglected Tropical Diseases	23
3.3. SDG 3: End of Ntds Epidemic	23
3.4. U.S. Government Efforts	23
3.5. Multidimensional and Other Efforts	24
3.6. Funding	24
4. COVID 19 AND IMPACT ON NTDs	25

CONCLUSION	26
REFERENCES	27
CHAPTER 3 CURRENT THERAPEUTIC STRATEGIES FOR THE MANAGEMENT OF LEPROSY	30
<i>Inderjeet Verma, Dhirender Singh, Meenakshi Dhanawat and Sumeet Gupta</i>	
1. INTRODUCTION	30
2. EPIDEMIOLOGY	31
2.1. Etiologic Agent, the <i>Mycobacterium leprae</i> (<i>M. leprae</i>)	32
2.2. Genetic Determinants of Host Response	32
2.3. Transmission of Leprosy	33
2.4. Risk Factors	33
2.5. Interaction of <i>M. leprae</i> with Schwann Cells and Macrophages	33
2.6. Clinical Signs and Classifications	34
2.6.1. Tuberculoid Leprosy	37
2.6.2. Lepromatous Leprosy	37
2.6.3. Borderline Leprosy	38
2.7. Diagnosis of Leprosy	38
2.8. Leprosy Treatment Approaches	39
2.9. Issues and Challenges of Leprosy Treatment	40
CONCLUSION	41
REFERENCES	42
CHAPTER 4 EMERGING THERAPY FOR DENGUE	48
<i>Inderjeet Verma, Meenakshi Dhanawat, Garima Malik, Arti Saini and Poonam Bharti</i>	
1. INTRODUCTION	48
1.1. Classification	50
2. ETIOPATHOGENESIS	51
2.1. Symptoms and Signs	52
2.2. Bioanalysis Methods for Anti-dengue Activity	52
2.2.1. Pre-clinical	52
2.2.2. Clinical	53
2.3. Treatment	54
2.3.1. Symptomatic Management	54
2.3.2. Management of the Critical Phase	54
2.3.3. Fluid Resuscitation	54
2.3.4. Blood Products	55
2.3.5. Immunomodulation	55
2.3.6. Corticosteroids	56
2.3.7. Intravenous Immunoglobulins	56
2.3.8. Other Supportive	56
2.3.9. Nucleoside Analogues	58
2.3.10. RNA Dependant RNA Polymerase(NS5) Inhibitor	58
2.3.11. Protease(NS2b-NS3) Inhibitors	58
2.3.12. Quinoline Containing Compounds	58
2.3.13. NS4b Inhibitor	58
2.3.14. Host Modulators	59
3. RIBAVIRIN	59
3.1. Mycophenolic Acid	59
3.2. A Glycosidase Inhibitors	59
3.3. Lovastatin	59

3.4. Host Kinase Inhibitors	60
3.5. Heparin and Heparan Sulfate	60
3.6. Interferon	60
3.7. D4 Dopamine Receptor Antagonists	60
3.8. Pentoxifylline	60
3.9. Ivermectin	61
4. CHLOROQUINE	61
4.1. RNAi	61
4.2. Medicinal Plant Derivatives	61
CONCLUSION	61
REFERENCES	62
CHAPTER 5 LYMPHATIC FILARIASIS AND DRACUNCULIASIS	66
<i>Anjali Sharma, Devkant Sharma, Srishti Vats, Akash Kamboj and Prerna Sharma</i>	
1. INTRODUCTION	66
2. CAUSES AND TRANSMISSION	67
3. LIFECYCLE	67
4. CLINICAL MANIFESTATIONS OF LYMPHATIC FILARIASIS	69
4.1. Acute Disease	69
4.2. Chronic Disease	69
5. PATHOGENESIS	70
6. DIAGNOSIS	71
7. APPROACHES TO CONTROL AND ELIMINATE THROUGH MDA	72
8. WHO RECOMMENDATIONS FOR MDA TO ELIMINATE LYMPHATIC FILARIASIS	73
9. FUTURE CONSIDERATIONS	74
10. RISK FACTORS	75
11. INTRODUCTION TO DRACUNCULIASIS	75
11.1. Genus Dracunculus	76
11.2. Species of Dracunculus	76
11.3. Dracunculus Insignis	76
11.4. Dracunculus Lutrae	76
11.5. Dracunculus Fuelleborn	77
12. TRANSMISSION	77
13. CURRENT STATUS IN INDIA	78
14. GLOBAL SITUATION	78
15. ERADICATION OF GUINEA WORMS IN INDIA	78
16. LIFE CYCLE AND CLINICAL IMPACT	78
17. AREAS OF ERUPTION	80
18. DIAGNOSTIC FEATURE	80
19. TREATMENT	81
20. ECONOMIC IMPACT	81
21. THE ROAD TO ERADICATION	82
CONCLUDING REMARKS	82
REFERENCES	83
CHAPTER 6 CURRENT THERAPEUTIC STRATEGIES FOR SOIL-TRANSMITTED HELMINTHIASIS	91
<i>Ashwani Arya, Suchitra Nishal, Renu Kadian and Manish Dhall</i>	
1. INTRODUCTION	92
2. CLINICAL FEATURES OF HELMINTHIASIS	93
2.1. Mode of Transmission of Helminth Infection	93

2.2. Nutritional Effects of Helminthiasis	94
2.3. Diagnosis of STH	94
2.4. Pathophysiology of STH	95
2.5. Therapeutic Strategies for Soil-transmitted Helminthiasis	97
2.6. Different Drug Administration Strategies	98
2.7. Drugs Recommended by WHO for the Treatment of Soil-transmitted Helminthiasis ...	98
2.8. Risk Groups for Infection	99
2.9. The Intervention of Soil-transmitted Helminthiasis	99
2.10. Ayurvedic Strategies for Soil-transmitted Helminthiasis	99
2.11. Prevention of Helminth Infection	102
2.11.1. Health Education	102
2.11.2. Regular Treatment	103
2.11.3. Sanitation	103
3. FUTURE ASPECTS	103
CONCLUSION	104
REFERENCES	104

CHAPTER 7 CURRENT THERAPEUTIC STRATEGIES FOR NEUROCYSTICERCOSIS AND LESHMANIASIS 112

Nitin Goel, Arvinder Kaur, Lalit Gupta, Rajiv Sharma, Satvinder Kaur, Vishnu Mittal and Vani Dawar

1. INTRODUCTION	113
2. THE PARASITE	114
3. CLINICAL MANIFESTATION	115
4. DIAGNOSIS AND TREATMENT OF NCC	116
4.1. Conventional Diagnosis	116
4.1.1. Excision Biopsy	116
4.1.2. Neuroimaging	116
4.1.3. Methods for Immunological Diagnosis Based on Blood or Serum	117
4.1.4. Antigen Detection Tests	117
4.2. Novel Methods of Diagnosis	118
4.2.1. Fast Imaging Utilizing Consistent State Securing	118
4.2.2. Microscopic Assessment of Defecation for Taenia Eggs	118
4.2.3. DNA-based Methods	119
4.3. Management of NCC	119
4.3.1. Surgery	119
5. CURRENT MEDICATIONS FOR NCC TREATMENT	119
5.1. Corticosteroids	120
5.2. Antiepileptic Drugs	120
5.3. Praziquantel (biltricide, cysticide, prazisan)	120
5.4. Albendazole	121
5.5. Combination Regimen	122
6. LIMITATIONS/DRAWBACKS OF CURRENTLY USED DRUGS	127
7. FUTURE PROBLEMS AND THEIR ANSWERS	128
7.1. Leishmaniasis	128
7.1.1. Introduction	128
7.1.2. Epidemiology	129
7.1.3. Causative Agent	131
7.1.4. Diagnosis	132
7.1.5. Pathophysiology/Life Cycle of Leishmania	133
7.1.6. Types and Clinical Manifestations	134

7.1.7. Cutaneous Leishmaniasis (CL)	135
7.1.8. Mucocutaneous leishmaniasis (MCL)	136
7.1.9. Visceral leishmaniasis (VL)	137
7.1.10. Treatment Goals	139
8. TRADITIONAL ANTILEISHMANIAL TREATMENT	140
8.1. Pentavalent Antimonial	140
8.2. Amphotericin B	141
8.3. Pentamidine	141
8.4. Miltefosine	141
8.5. Paromomycin	142
8.6. Azoles	143
8.7. Allopurinol	143
8.8. Sitamaquine	143
8.9. Other Drugs	144
9. NEW STRATEGIES FOR LEISHMANIASIS	145
9.1. Modern Strategies for CL and MCL	145
9.1.1. Local and Physical Therapies	145
9.1.2. Topical Drug Treatment Options	147
9.2. Modern Strategies for Visceral leishmaniasis	148
9.2.1. Combination/Multi-drug Therapy	148
9.2.2. Immunity Boosters	148
9.2.3. Microspheres	149
9.2.4. Nanotechnology	150
9.2.5. Drug Repurposing	153
9.2.6. Phytochemicals/Plants Used	153
9.2.7. Photodynamic Therapy	155
9.2.8. Vaccines	155
CONCLUSION	155
ABBREVIATIONS	155
REFERENCES	157
CHAPTER 8 CURRENT THERAPEUTIC STRATEGIES FOR BURULI ULCER	166
<i>Manisha Bhatia, Jasmine Chaudhary, Akash Jain and Ashwani Dhingra</i>	
1. INTRODUCTION	167
2. ULCERS	167
2.1. Types of Ulcers	168
2.1.1. Decubitus Ulcers	168
2.1.2. Venous Ulceration	168
2.1.3. Arterial Ulcers	168
2.1.4. Neuropathic Ulcers	169
2.1.5. Vasculitis Ulcer	169
3. BURULI ULCER	169
3.1. Causative Organism	170
3.2. Epidemiology	170
3.3. Progression of the Disease	171
3.4. Pathogenesis	172
4. CURRENT CONTROL STRATEGY	173
5. TREATMENT REGIMEN	174
6. CHALLENGES	175
7. PREVENTION	176
CONCLUSION	177

REFERENCES	178
CHAPTER 9 CURRENT THERAPEUTIC STRATEGIES FOR TRACHOMA	182
<i>Himani Bajaj, Sindhu Agarwal, Anjali Sharma, Mayank Yadav and Md. Arif Naseer</i>	
1. INTRODUCTION	182
2. CHLAMYDIA TRACHOMATIS	183
2.1. Symptoms and Signs	183
2.2. Stages of Trachoma	184
2.2.1. Follicular Inflammation	184
2.2.2. Severe Inflammation	184
2.2.3. Twisted Eyelashes (trichiasis)	184
2.2.4. Cloudy Cornea (Opacity)	184
2.3. Causes	185
2.4. Risk Elements	185
2.4.1. Congested Housing Situations	185
2.4.2. Deficient Sanitation	185
2.4.3. Age	185
2.4.4. Sex	185
2.4.5. Flies	185
3. CYCLE OF CHLAMYDIAL DEVELOPMENT	185
3.1. Affiliation and Invasion	187
3.2. Modification of the Intracellular Environment	187
3.2.1. Included Organelles and Size	188
3.2.2. Inclusion and Lipids	188
3.2.3. Alteration of the Metabolic Pathway	188
3.3. Host Evasion	188
3.4. Host Exit	189
4. COMPLICATIONS	189
5. PREVENTION	190
5.1. Washing your Hands and your Face	190
5.2. Fly Management	190
6. SURGERY	191
7. ANTIBIOTICS	191
8. FACE CLEANING	193
9. ECOLOGICAL FACTORS	193
CONCLUSION	194
REFERENCES	194
CHAPTER 10 CURRENT THERAPEUTIC STRATEGIES FOR FOOD BORNE TREMATODIASES	200
<i>Nidhi Gupta, Inderjeet Verma and Hasandeep Singh</i>	
1. INTRODUCTION	200
2. THE LIFE CYCLE OF FOOD-BORNE TREMATODES	201
3. GEOGRAPHIC DISTRIBUTION	202
4. SYMPTOMS	202
4.1. Clonorchis Sinensis	203
4.2. Fasciola Hepatica and Fasciola Gigantica	203
4.3. Opisthorchis Viverrini	203
4.4. Paragonimus spp.	204
5. DIAGNOSIS	204
5.1. Parasitological Diagnosis	205

5.2. Immunodiagnosis	205
5.3. Molecular Techniques	206
6. CURRENT THERAPEUTIC STRATEGIES USED IN THE TREATMENT OF FOOD- BORNE TREMATODIASES	206
6.1. Prevention, Treatment and Control	206
6.2. Chemotherapy	207
6.3. <i>In vitro</i> Activity of Natural Plant Extracts	209
CONCLUSION	210
ACKNOWLEDGEMENT	211
REFERENCES	211
SUBJECT INDEX	215

PREFACE

This work will lead to an extensive debate as it covers an interesting topic. I feel compelled to share my knowledge, analyses, and conclusions after working for numerous years in the field of pharmacy. I have written many papers and book chapters on various aspects. Perhaps this description will increase the knowledge of the issue and initiate a discussion that could result in significant ideological transformations. There are two reading categories for this book. First off, it can be read by individuals with little to no prior knowledge of science. Professionals from academia and government organizations are the second set of readers. It is hard to believe that all members of the scientific community will comply with the concepts and ideas presented in this work. But I do hope that the knowledge and information provided will serve as a guide for all the sections of society.

Neglected tropical diseases (NTDs) are a diverse collection of 20 illnesses that are primarily found in tropical regions and impact more than 1 billion people who reside in underdeveloped communities. Numerous pathogens, such as viruses, bacteria, parasites, fungi, and toxins, are responsible for their development. More than one billion people suffer from terrible health, along with social, and fiscal effects of these diseases. There are 12 chapters in the book. The introduction to neglected diseases is broadly introduced in Chapter 1 of this book. The strategies to overcome the impact of neglected diseases on the world are discussed in Chapter 2, which also provides a step-by-step process to handle such conditions. The current therapeutic strategy for leprosy, dengue, lymphatic filariasis and dracunculiasis, helminthiasis, Chagas disease, neurocysticercosis and leishmaniasis, rabies, trematodiasis, Buruli ulcer and trachoma is introduced in Chapter 3 to 10, respectively, along with an account of the possible disease mechanism, transmission and management protocols.

I wish a lot of people read this book. In order to escape the mistakes of the past, we must alter course and begin utilising knowledge built up by scientists.

Prerna Sharma

Guru Gobind Singh College of Pharmacy
Yamunanagar, India

Sumeet Gupta

MM College of Pharmacy
MMU, Mullana, Haryana
India

Hitesh Malhotra

Guru Gobind Singh College of Pharmacy
Yamunanagar, India

Bhawna Chopra
Guru Gobind Singh College of Pharmacy
Yamunanagar, India

&

Sunil Sharma
Guru Jambheshwar University of Science and Technology
Hisar, India

List of Contributors

Anjali Sharma	Guru Gobind Singh College of Pharmacy, Yamunanagar, India
Arti Saini	M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala-133207, Haryana, India
Akash Kamboj	Guru Gobind Singh College of Pharmacy, Yamunanagar, India
Ashwani Arya	Department of Pharmaceutical Education and Research, BPS Women University, Sonapat, Haryana, India
Arvinder Kaur	G.H.G. Khalsa College of Pharmacy, Gurusar Sadhar, Ludhiana, India
Akash Jain	M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala-133207, Haryana, India
Ashwani Dhingra	Guru Gobind Singh College of Pharmacy, Yamunanagar, Haryana, India
Dhirender Singh	M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala-133207, Haryana, India
Devkant Sharma	CH. Devi Lal College of Pharmacy, Jagadhari, India
Garima Malik	M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala-133207, Haryana, India
Himani Bajaj	AVIPS, Shobhit University, Gangoh, Saharanpur, UP, India
Hasandeep Singh	Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab-143005, India
Inderjeet Verma	M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala-133207, Haryana, India
Jasmine Chaudhary	M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala-133207, Haryana, India
Kashish Wilson	M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala-133207, Haryana, India
Lalit Gupta	G.H.G. Khalsa College of Pharmacy, Gurusar Sadhar, Ludhiana, India
Meenakshi Dhanawat	Amity Institute of Pharmacy, Amity University Haryana, Gurugram, Haryana, India
Manish Dhall	College of Pharmacy, PGIMS (SDPGIPS), Pt. B. D. Sharma University of Health Sciences, Rohtak-124001, Haryana, India
Manisha Bhatia	M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala-133207, Haryana, India
Mayank Yadav	AVIPS, Shobhit University, Gangoh, Saharanpur, UP, India
Md. Arif Naseer	AVIPS, Shobhit University, Gangoh, Saharanpur, UP, India
Namratha MP	JSS Academy of Higher Education and Research, Mysore, India
Nitin Goel	G.H.G. Khalsa College of Pharmacy, Gurusar Sadhar, Ludhiana, India
Nidhi Gupta	M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala-133207, Haryana, India
Pooja Mittal	Chitakara College of Pharmacy, Chitkara University, Rajpura, Punjab, India

iv

Poonam Bharti	Department of Psychology, MMIMSR, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala-133207, Haryana, India
Prerna Sharma	Guru Gobind Singh College of Pharmacy, Yamunanagar, India
Renu Kadian	Ram Gopal College of Pharmacy, Sultanpur, Farrukhnagar, Gurgaon-122507, Haryana, India
Rajiv Sharma	University Institute of Pharma Science Chandigarh University, Gharuan, Mohali, India
Sumeet Gupta	M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala-133207, Haryana, India
Srishti Vats	Guru Gobind Singh College of Pharmacy, Yamunanagar, India
Suchitra Nishal	College of Pharmacy, PGIMS (SDPGIPS), Pt. B. D. Sharma University of Health Sciences, Rohtak-124001, Haryana, India
Satvinder Kaur	University Institute of Pharma Science Chandigarh University, Gharuan, Mohali, India
Sindhu Agarwal	AVIPS, Shobhit University, Gangoh, Saharanpur, UP, India
Vishnu Mittal	Guru Gobind Singh College of Pharmacy, Yamunannagar, Haryana, India
Vani Dawar	Guru Gobind Singh College of Pharmacy, Yamunannagar, Haryana, India

Neglected Tropical Diseases

Garima Malik^{1*}, Meenakshi Dhanawat² and Kashish Wilson¹

¹ M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, Haryana, 133207, India

² Amity Institute of Pharmacy, Amity University Haryana, Gurugram, Haryana, India

Abstract: Neglected tropical diseases (NTDs) are a widespread category of communicable illnesses that thrive in tropical and subtropical environments. More than a billion people are affected by these illnesses, which annually drain billions of dollars from developing nations' economies. The most severely impacted populations are those who lack access to basic sanitation, live in poverty, and are in close proximity to disease vectors, domestic animals, and livestock. The World Health Organization (WHO) is a United Nations department focusing on public health issues. NTDs pose a significant threat to public health both globally and in India. Lymphatic filariasis (LF), Visceral Leishmaniasis (VL), Rabies, Soil-Transmitted Helminthic Infections (STH), and Dengue are the principal parasitic and associated infections that the World Health Organization (WHO) has designated as neglected tropical diseases (NTDs). These neglected diseases represent a concern to millions of underprivileged Indians who live in deplorable conditions. The current chapter examines the common NTDs in India, their prevalence, the state of control strategies, and obstacles and prospects for NTD eradication.

Keywords: Communicable diseases, Diseases of poverty, Epidemiology, Global burden, Integrated control, Mass drug administration, Neglected Tropical Diseases, Poverty, Risk factors, World Health Organization.

1. INTRODUCTION

Neglected tropical illnesses are a serious issue for public health since they affect almost one billion people worldwide [1]. Regardless of the fact that these illnesses have been known for centuries, many nations, especially low- and middle-income ones (LMIC), are still working to eradicate NTDs [2]. The WHO classified seventeen significant parasite infections and associated disorders as neglected tropical diseases. These illnesses disproportionately affect the underprivileged and

* **Corresponding author Garima Malik:** M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, Haryana, 133207, India; E-mail: garimamalik912@gmail.com

poor populations of countries in Africa, Southeast Asia, and South America [3 - 5]. A massive campaign aimed at public health control and elimination of these diseases is closely related to neglected tropical diseases (NTDs), a group of tropical infections [6 - 8].

The three main types of diseases in India are communicable diseases, maternity and child health issues (which collectively account for around half the burden), and non-communicable disorders [9]. Thus, both the diseases of the industrialized world (such as diabetes mellitus and cardiovascular diseases) and the ailments of the underdeveloped world (such as infectious and neglected diseases) have been observed in India [10]. The recurrence of previously curable illnesses like leishmaniasis, malaria, and other vector-borne diseases has a major impact on underprivileged and rural populations. However, these diseases have received little attention globally because they primarily affect the poorer sections of the population. Thus, it will be appropriate to state that neglected diseases are a category of infectious and parasitic illnesses that often receive little attention from the pharmaceutical industry and mainly afflict the poorest members of society [11].

Upon the introduction of the Millennium Development Goals (MDGs) in the early 2000s, the NTD framework was initially put forth. HIV/AIDS, TB, and malaria were expressly included in the MDG's list of global infectious diseases, leaving out numerous tropical diseases with significant worldwide recurrence and disease burden. In response, 13 bacterial, protozoal, and helminthic “neglected” infectious disorders were grouped as NTDs. Later, WHO divided the NTDs into two groups: (1) individuals treated with preventative chemotherapy and transmission control (PCT) and (2) those demanding novel and rigorous disease management (IDM). The seven PCT-related illnesses were grouped based on the idea that they may all be treated at the same time with a “rapid-impact package” of drugs by mass drug administration (MDA; also known as preventative chemotherapy), as shown in Fig. (1) [12].

Schistosomiasis, lymphatic filariasis (LF), onchocerciasis, and trachoma were among the PCT disorders, as were the three major soil-transmitted helminth (STH) diseases (ascariasis, trichuriasis, and hookworm) [7]. As worldwide control and elimination operations gained significance internationally, the WHO formed a Department of NTDs and eventually added 18 major tropical illnesses to the NTD list. WHO has recently increased this figure to 20. In this book chapter, we review the public health initiatives for the control and eradication of NTDs, discuss current worldwide developments, and map a course for the future.




Fig. (1). A compendium of Neglected Tropical Diseases. Much attention is given to previously neglected diseases such as malaria, HIV/AIDS, and TB. In contrast, schistosomiasis and soil-transmitted helminthiasis continue to be overlooked; this also includes zoonosis diseases from the interactions of humans and their animals.

2. EPIDEMIOLOGY AND RISK FACTORS

To end the neglected tropical diseases for the achievement of goals incorporated in sustainable evolution, a protocol, namely 2021-2030 Neglected Tropical Diseases, has been adopted by the WHO Director-General and the Director of the Department of Control of Neglected Tropical Diseases.

The primary objectives of the year 2030 for neglected tropical disease awareness are listed below:

- Individuals needing therapy for NTDs decreased to 80-90% in particular areas.
- Approximately ten nations are in the process of eliminating NTDs.
- The most defined diseases, such as yaws and dracunculiasis, must be eliminated.
- All the matters related to NTDs, such as Disability-Adjusted Life Years, need to produce a 70-75% decline [13].

A ground plan helps in monitoring various distinct infections as well as setting standard targets for multiple factors, which includes decreased vector-instilled NTDs mortality within the limit of 70-75% along with the promotion of maximum ingress in supplying water as well as cleaning and sanitation procedure in various areas where NTDs is in the native range. The high expense of

Strategies to Overcome the Impact of Neglected Diseases on the World

Namratha MP¹, Pooja Mittal^{2*}, Anjali Sharma³ and Vishnu Mittal³

¹ JSS Academy of Higher Education and Research, Mysore, India

² Chitakara College of Pharmacy, Chitkara University, Rajpura, Punjab, India

³ Guru Gobind Singh College of Pharmacy, Yamunanagar, Haryana, India

Abstract: Neglected tropical diseases (NTDs) are highly prevalent in Sub-Saharan Africa. In the World Bank's definition of poverty, nearly all people suffer from at least one NTD. Among the most widespread NTDs are malaria, HIV, and soil-transmitted helminths like lymphatic filariasis, schistosomiasis, trachoma, and onchocerciasis. A recent study suggests that NTDs may influence the evolution of HIV and AIDS, malaria, and tuberculosis. These interactions may be influenced by epidemiological, immunological, and clinical factors, which may impair the prognosis for those with HIV/AIDS, TB, or malaria. World Health Organization (WHO) suggests five main strategies for preventing and controlling NTDs for public health-intensified case management, vector control, preventive chemotherapy, sanitation, the provision of safe water, veterinary public health, and hygiene. Despite only using one method and doing it locally, to control, and eliminate the NTDs, these methods can be used as a mark for achieving the Sustainable Development Goals as they are mainly found in disadvantaged regions and environments. The development of pilot projects and initiatives can help achieve the Millennium Development Goals. The poor and marginalised could gain from innovative treatments for neglected diseases (particularly parasite infections) based on sustainability concepts and knowledge of key factors affecting health.

Keywords: AIDS, Epidemiological, Immunological, Neglected tropical diseases, Tuberculosis, World Health Organization.

1. INTRODUCTION

A collection of infections known as neglected tropical diseases (NTDs) are the most common among low-level income people in developing nations, particularly in Africa, the Americas, and Asia. Because neither medication and diagnostics de-

* **Corresponding author Pooja Mittal:** Chitakara College of Pharmacy, Chitkara University, Rajpura, Punjab, India; Tel: +918874774515, +918817645059; E-mail: poojamittal2009@gmail.com

velopers nor public health programs have adequately addressed certain ailments, they are categorized as neglected diseases. At least 100 of the 149 nations and territories where NTDs are recorded have two or more endemic diseases, with 30 having six or more [1]. In all afflicted regions, NTDs now result in unacceptably high levels of human misery and death. For instance, the overall impact of NTDs in sub-Saharan Africa is comparable to the worldwide burden of both malaria and tuberculosis. Many NTDs also increase the lethality of diseases like HIV/AIDS and TB through co-infection. Although there are several preventative strategies and medical treatments for these illnesses in high-income nations, they are not easily available in low- and middle-income nations. The NTDs that the World Health Organization (WHO) has prioritized have been grouped despite their varied medical profiles because of their propensity to co-exist geographically and because they share some characteristics [2]. Combining various diseases makes it easier to calculate their combined burden and relevance to public health and elevates their profile to help with resource collection. Despite the prevalence of NTDs, funds granted for research and treatment of other diseases including HIV/AIDS, TB, and malaria have typically outpaced that of NTDs. Recently, considerable efforts have been made to combat NTDs as the global health community has recognized their significant burden. The WHO's plan to eradicate, eliminate, or control 10 NTDs was supported by the London Declaration, which was signed in 2012 by governments, nonprofit organizations, pharmaceutical firms, and the WHO [3]. Diagnostics are very crucial to determining the extent of transmission, assisting in the timing of the termination of MDA programs, confirming the end of transmission, and monitoring to ensure sustained elimination. When determining whether a disease is present or absent and assisting in the selection of a course of therapy, diagnostics offer objective and quantitative data. Diagnostics are needed to identify specific patients to administer therapy for NTDs such as leprosy, sleeping sickness, leishmaniasis, and Chagas disease that are not managed by MDA. Additionally, the first of the seven top research priority for Chagas disease, leishmaniasis, and human African trypanosomiasis (HAT) identified by the WHO's Special Programmes for the Research and Training in Tropical Diseases (WHO/TDR) is diagnostics for case detection and characterization, includes the tests to drug resistance and for a cure. Therefore, resolving the diagnostic requirements for these NTDs has emerged as a top priority to accomplish the goals of the London Declaration [4]. It will be vital to form alliances with many other sectors capable of taking effective action. Lowering of NDs will ultimately help communities suffering from poverty to develop sustainably, and it also helps the countries affected by these diseases experience greater economic growth [5].

As they say "Prevention is better than cure", preventive measures need to be taken to reduce the impact of NDTs on the world.

2. IMPACT OF NTDs

NTDs have high rates of morbidity but low rates of mortality. (World Health Organization. Department of Control of Neglected Tropical Diseases, n.d.) According to the data, about 1/6th of the population is suffering from NTDs and we can say about a billion people are suffering from NTDs and an extra 2 billion are at risk of developing NTDs. Consequently, around 185,000 people pass away every year. People frequently carry many NTDs at once, which can cause severe deformity, disability, blindness, and starvation because of infection [6]. NTDs' health consequences negatively impact economic development, educational success, cognitive development, agricultural production, and food security. NTDs are endemic to about 150 nations worldwide. However, middle and low-income nations in America, Africa, Latin, Asia, and Africa bear the lion's share of the burden of NTDs. Due to the incidence and effect of NTDs, those living in urban slums and rural regions are among the most exaggeratedly spoilt, due to no access to clean water, good sanitation, health services, and suitable housing. Since they are more likely to be exposed to NTDs and encounter hurdles to treatment more frequently, particularly those who live in remote locations, children and women are most at risk for infection [7].

2.1. To Defeat the Impact of NTDs on World's Health and Economy

Several approaches partake be, effective in limiting and, in about cases, even eliminating various NTDs. The four selected NTDs cause considerable morbidity, and might even lead to death and all have a significant economic impact on the already impoverished populations they affect. We believe that the economic impact of COVID-19 on these populations will be severe and long-lasting. There have been several effective approaches in limiting and, in some cases, even eliminating various neglected tropical diseases (NTDs) [8]. Here are a few examples:

2.1.1. Mass Drug Administration (MDA)

MDA involves distributing preventive medications to large populations at risk of specific NTDs. This approach has been successful in controlling diseases like lymphatic filariasis and schistosomiasis [9].

2.1.2. Improved Sanitation and Hygiene

Enhancing access to clean water, and proper sanitation facilities, and promoting good hygiene practices can significantly reduce the transmission of NTDs like soil-transmitted helminthiasis and trachoma [10].

Current Therapeutic Strategies for the Management of Leprosy

Inderjeet Verma^{1,*}, Dhirender Singh¹, Meenakshi Dhanawat² and Sumeet Gupta¹

¹ MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana Ambala-133207, Haryana, India

² Amity Institute of Pharmacy, Amity University Haryana, Gurugram, Haryana, India

Abstract: The chronic infectious condition known as leprosy is brought on by the bacteria *Mycobacterium leprae*. Peripheral nerves and the skin are frequently attacked, which can result in impairments. The incidence of *M. leprae* infection has decreased in endemic countries as a result of the WHO's multidrug therapy (MDT) program for leprosy treatment, but there is still active transmission as evidenced by the high rate of newly reported cases. It is critical to diagnose leprosy as early as possible, hence clinical examination and research are required. Leprosy has six subgroups, according to the Ridley-Jopling classification: Tuberculoid (TT), Borderline Tuberculoid (BT), Borderline-borderline Mid-borderline (BB), Borderline-lepromatous (BL), Subpolar Lepromatous (LLs), and Polar Lepromatous (LLp). Based on the type of therapy, leprosy is categorised into paucibacillary (PB) and multibacillary subtypes (MB). Skin scraping smears are still the preferred laboratory test for leprosy diagnosis. Depending on the type of leprosy, whether it belongs to the PB or MB group, the course of treatment with Multi-Drug Therapy (MDT) is modified. Rifampicin and dapsone are the recommended regimens for the treatment of PB type, whereas rifampicin, dapsone, and clofazimine are recommended for MB-type patients. To identify an efficient MDT treatment and stop the spread of the illness, a correct leprosy diagnosis must be made by both a physical examination and a laboratory analysis.

Keywords: Dapsone, Leprosy, *Mycobacterium leprae*, Multi-Drug Therapy, Rifampicin.

1. INTRODUCTION

Leprosy, a highly infectious chronic disease discovered by Gerhard Armer Hansen of Norway in 1873, is still a big issue in many parts of the world [1]. *Mycobacterium leprae* an acid-fast rod-shaped bacillus is the main causative

* Corresponding author Inderjeet Verma: MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana Ambala-133207, Haryana, India; E-mail: indupup@gmail.com

agent of leprosy which primarily affects the skin and peripheral nerves, but also the muscles and other body parts [2, 3]. In the current scenario, leprosy is globally one of the principal causes of non-traumatic peripheral neuropathy. Despite developments in neglected countries, mostly in Southeast Asia and the Americas leprosy still remains widespread in a number of areas [4]. From 2005 till 2014, globally the count of reported cases remains unchanged, as a result, leprosy remains widespread in many areas even after a decade [5]. In 2019, over 1000 new cases were reported in 13 nations, which is more than 95% of new cases.




Fig. (1). Geographical distribution of leprosy cases. Courtesy of WHO. (10,11).

2. EPIDEMIOLOGY

In 1966, the first global data was published on the disease prevalence, (however, in 1953 in Rio de Janeiro(Brazil), the first-ever expert committee (WHO) on leprosy was formed. In those days, the expected figure of leprosy globally was more than 10 million even though the disease was underestimated. The leprosy cases remained stable till 1980, ranging from 10-12 million [6, 7]. From 1982 onwards, the initiation of multi-drug therapy leads to sharp decline in cases of leprosy. (5.5 million till 1991) [8]. This encouraging number inspired the members of the 44th meeting of the World Health Assembly (WHA) to pass the 44.9 resolution with the intention to eliminate leprosy as of the year 2000 *i.e.*, the cases should be less than 1/10,000 population [9]. This initiation will result in a significant decrease in the number of cases from 719,219 million to 265,661 million from 2000 to 2006. Unfortunately, this decrease in annual cases reached a

plateau after 2006. From 2017 onwards, there was a slight decrease in the number of cases [10].

Among the newly reported cases, India comes at number one with a 60% share, however, Brazil and Indonesia come next with 13% and 8% share respectively [11]. The number of cases continues to fall, still in some parts of the world, where the prevalence of this disease is very normal, including India, Nepal, Brazil, Bhutan, Tanzania, Mozambique, Madagascar, and the western Pacific. A very few cases were identified in the USA each year [12] (Fig. 1).

2.1. Etiologic Agent, the *Mycobacterium leprae* (*M. leprae*)

M. leprae, which is the main causative agent is an acid-fast bacillus, which has not yet been cultured *in vitro*, however, the bacterium was successfully grown *in vivo* into the footpads of mice [13, 14]. The bacterium is notorious and slow in growth with an exponential time of 14 days [15, 16].

Sequencing of *M. leprae* revealed a substantial number of pseudogenes and less than 50% coding capability. The rest 50% genes from *M. leprae* are used to define the minimal gene set necessary for this mycobacterial pathogen to survive *in vivo* as well as genes that might be important for leprosy infection and pathogenesis [17].

A recently discovered mycobacterium called *M. lepromatosis* is characterised as a causing agent for disseminated leprosy, but its significance is not yet unclear [18, 19].

2.2. Genetic Determinants of Host Response

The possibility of developing leprosy and the disease's clinical course is influenced by human genetic factors [20]. In single-nucleotide polymorphism (SNP) association analyses, a low lymphotoxin-producing allele (LTA) was identified as a major genetic risk factor for early-onset leprosy [21]. Additionally, it has been proposed that SNPs in the vitamin D receptor (VDR), IL-10, TNF, HLA, IFN genes and TLR1 may be linked with sickness and/or the onset of reactions in other genes [22 - 25]. In the promoter sequence shared through two genes, PARK2, which codes for the E3-ubiquitin ligase known as Parkin, and PACRG, linkage analysis have shown polymorphic threat factors [26]. Additionally, a study reveals that NOD2 genetic variations are linked to leprosy susceptibility and the emergence of responses (type I and type II) [27].

Emerging Therapy for Dengue

Inderjeet Verma^{1*}, Meenakshi Dhanawat², Garima Malik¹, Arti Saini¹ and Poonam Bharti³

¹ M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala-133207, Haryana, India

² Amity Institute of Pharmacy, Amity University Haryana, Gurugram, Haryana, India

³ Department of Psychology, MMIMSR, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala-133207, Haryana, India

Abstract: There are over 60 countries where dengue fever is endemic, and 2.5 billion people could get sick from it. An RNA virus belonging to the Flaviviridae family that causes acute viral disease dengue is transmitted by *Aedes* mosquitoes. The presenting signs may be asymptomatic fever with severe implications such as hemorrhagic fever and shock. The most common symptoms are acute-onset high fever, cutaneous rash, hemorrhagic episodes, myalgia and circulatory shock. Although oral symptoms are seldom the primary presenting sign of dengue infection, they may occur in certain cases. Early and precise diagnosis is necessary for lowering mortality. Dengue virus infections are typically self-limiting, but in tropical and subtropical countries, dengue infection has become a public health threat. A detailed explanation of dengue virus infections, clinical symptoms, diagnostic techniques, and preventative measures are all included in this book chapter.

Keywords: *Aedes aegypti*, Dengue, Fever, Immunological, Virus infections.

1. INTRODUCTION

Dengue is a fever infection that, in extreme circumstances, can be severe. It is brought on by one of four different serotypes of the flavivirus (DV-1 to DV-4) [1]. *Aedes aegypti* and the virus spread by *Aedes albopictus* mosquitoes, which are carriers of the virus among humans [2]. The precise pathophysiology of severe dengue disease remains unknown, despite the fact that it is now well-acknowledged that the pathogen virulence, host genetic makeup and host immune system are all factors in the fast deterioration observed in certain patients [3]. In the tropics, dengue is a serious public health issue because of its increased occur-

* Corresponding author Inderjeet Verma: M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala-133207, Haryana, India; E-mail: indupup@gmail.com

ence. With waves of outbreaks occurring after each rainy season, dengue infections are closely related to seasonal climate change [4]. Thousands of people could be impacted by an outbreak. This results in a large mortality rate in many afflicted locations, which is prevalent primarily among early childhood and working-age adults. The inability to treat specific cases, the lack of a vaccine for prevention, the existence of four different virus serotypes, each of which has the capacity to independently cause fatal disease, and difficulties in managing the vector population are the main causes dengue infection [5].

Other than supportive treatment and prudent hydration therapy, dengue fever has no specific treatment. Over the past 50 years, clinical studies have evaluated a variety of therapy options with varying degrees of success. The “critical time” or risk window for dengue, during which the patient may suddenly deteriorate, is only between 48 and 72 hours long [6]. A fatal outcome is unlikely if the patient is properly handled throughout this stage. Still, this necessitates constant observation and flexible management evaluation. In simple dengue, there are no aftereffects if the patient recovers from the orchitis, oophoritis, and encephalitis, which can have a long-term impact on a very small percentage of cases. For a brief period, infections shield against different dengue virus serotypes, but not against the same serotype [7]. Due to the limited resources in developing nations, close monitoring and treatment of epidemics are quite challenging when hospitals are overburdened with patients. Additionally, there are limited evidence-based therapy plans that target the specific pathophysiological aspects of the disease. Due to ignorance, a lot of patients arrive at the hospital late, often in shock, and their management is challenging. Many efforts are now focused on preventing transmission by managing vector populations due to practical challenges of treating an established dengue infection [8]. To stop the spread of the disease, a variety of vector control techniques have been tried, including physical (removing breeding grounds), chemical (using insecticides and larvicides), and biological (using microorganisms like *Bacillus thuringiensis*). However, the mosquito can reproduce in clear stagnant water in between the trunk and the leaves, making this a difficult task [9]. It is quite impossible to remove such environments. Nevertheless, despite these difficulties, certain curative and preventive techniques have been found recently to lower the mortality linked with dengue infection.

An update on dengue is given in this book chapter, including information on the disease's etiopathogenesis, diagnostic standards, treatment options, and research directions.

1.1. Classification

Despite these challenges, several preventative and therapeutic strategies for reducing dengue disease and preventing death have been studied in recent years. This review updates knowledge on dengue in relation to a number of crucial areas, including the disease's epidemiology, history, and preventive strategies, as well as potential directions for future study.

The three types of dengue fever listed in the 1997 classification are undifferentiated fever, DF, and DHF. Grades I through IV were added to the DHF division, as shown in Fig. (1).




Fig. (1). WHO classification of Dengue infections and grading of severity of DHF.

Grade I: Having only minor bruises.

Grade II: Uncontrollable bleeding elsewhere and into the skin.

Grade III: Medical indications of shock.

Grade IV: Strong pulse, shock, and the inability to take a blood pressure reading. In this instance, grades III and IV make up DSS [10, 11].

Lymphatic Filariasis and Dracunculiasis

Anjali Sharma^{1,*}, Devkant Sharma², Srishti Vats¹, Akash Kamboj¹ and Prerna Sharma¹

¹ Guru Gobind Singh College of Pharmacy, Yamunanagar, India

² CH. Devi Lal College of Pharmacy, Jagadhari, India

Abstract: In poor nations, helminthic illnesses are a major source of social, economic, and medical problems. These parasite illnesses affect a large number of people, and there are not enough effective treatments available. It is necessary to step up research on novel medications and treatments to address this pressing need. The lymphatic system is hampered by lymphatic filariasis, which can result in aberrant body part growth and cause discomfort, severe disability, and social stigma. As of 2018, there were 51 million cases, a 74% decrease from the 2000 commencement of the WHO's Global Programme to Eradicate Lymphatic Filariasis. With 27 cases documented in 2020, the devastating parasite disease dracunculiasis is almost completely eradicated. The transmission cycle takes between 10 and 14 months to complete after infection. The aim of the book chapter is to focus on pathogenesis, diagnosis, available treatment, and measures to eradicate these infections caused by helminthic parasites, which have been declared as neglected diseases by the World Health Organization.

Keywords: Dracunculiasis, Helminthic disease, Lymphatic filariasis, Neglected disease, WHO.

1. INTRODUCTION

Lymphatic filariasis is a condition brought on by a borne parasite that results in parasitic infection. It also goes by the name of elephantiasis, a painful and severely disfiguring condition. A neglected tropical illness is lymphatic filariasis (LF). When filarial parasites are transferred from mosquitoes to humans, infection results. Infection, which is often acquired in childhood, frequently causes subtle harm to the lymphatic system.

This parasitic condition, which is brought on by tiny, thread-like worms, is regarded as a neglected tropical disease (NTD) on a global scale. Only the human lymphatic system is home to these adult worms. The lymph system keeps the

* Corresponding author Anjali Sharma: Guru Gobind Singh College of Pharmacy, Yamunanagar, India;
E-mail: sharma.sharmaa.anjali@gmail.com

body's fluid balance in check and aids in the immune system's ability to combat illnesses [1]. People can develop lymphedema and elephantiasis, which results in a hydrocele, a protrusion in a man's scrotum. The leading global cause of irreversible impairment is lymphatic filariasis [2].

2. CAUSES AND TRANSMISSION

Infection with nematodes (roundworms) from the family Filariodidea, which are categorized as parasites, results in lymphatic filariasis. These thread-like filarial worms are classified into 3 categories:

- a) *Wuchereriabancrofti*, which causes 90% of cases,
- b) *Brugiamalayi*, the majority of the remaining cases are caused by this,
- c) *Brugiatimori*, is the third one [1].

The skin is where mature parasite larvae are implanted so they can enter the body. The transmission cycle is subsequently completed when the larvae travel to the lymphatic vessels where they develop into adult worms [1].

Lymphatic filariasis is spread by a variety of mosquito species, including the *Culex* mosquito frequently available in semi-urban as well as urban areas. *Anopheles* mosquito in remote areas and the last one is the *Aedes*, which resides on endemic Pacific islands [1].

Microfilariae are larvae that are immature in nature and capable of circulating in the blood with distinct nocturnal periodicity, are produced by the adult. Typically, the worms produce microfilariae for 5-8 years of their life. Mosquito bites are the main method of transmission for lymphatic filariasis [3].

Although they appear healthy on the outside, people with circulating microfilariae spread the virus to others through mosquitoes. Chronic filarial swellings cause significant illness in those who have them, but they no longer spread the infection. In India, *Wuchereriabancrofti*, a species, accounts for 99.4% of cases while *Brugiamalayi* is only 0.6 percent of the problem. The filarial worms in the adult stage reside in the lymphatic system's channels. A crucial component of the body's immunological defense system, the lymphatic system is a network of lymph nodes along with lymph veins that maintain the balance of fluid between blood and the nearby tissues [3].

3. LIFECYCLE

The larval stage of filarial nematodes takes place in mosquito vectors (the

intermediate host), and the adult stage takes place in humans (the definitive host). When an infected mosquito bites, it spreads the infection. During a blood meal, the contagious larvae (third-stage larva; L3s) penetrate the bite wound before moving to the lymphatic artery and lymph nodes, where they develop into adult worms (Fig. 1). Approximately 50,000 microfilariae can be produced each day by the female worm after mating. Then, depending on the type of parasite, millions of microfilariae are sporadically discharged into the host's blood circulation from the lymphatics. The lifespan of adult lymphatic filarial parasites is 5–10 years, whereas the lifespan of microfilariae is 6–12 months [4].




Fig. (1). Lifecycle of *wuchereria bancrofti* causing lymphatic filariasis.

Microfilariae are consumed by infected people after mosquito bites, their sheath gets shredded and it passes through the entire stomach wall and finally reaches the thoracic muscles. After a short span of time, these convert in the larvae which is the first stage and later mature into larvae that are responsible for causing infection. These infectious larvae then move to proboscis of the mosquito and through subsequent biting, they get transferred from person to person. A weakened lymphatic system may arise from infection, which is often acquired throughout childhood without any obvious symptoms [5].

CHAPTER 6

Current Therapeutic Strategies for Soil-Transmitted Helminthiasis

Ashwani Arya¹, Suchitra Nishal², Renu Kadian³ and Manish Dhall^{2,*}

¹ Department of Pharmaceutical Education and Research, BPS Women University, Sonapat, Haryana, India

² College of Pharmacy, PGIMS (SDPGIPS), Pt. B. D. Sharma University of Health Sciences, Rohtak-124001, Haryana, India

³ Ram Gopal College of Pharmacy, Sultanpur, Farrukhnagar, Gurgaon-122507, Haryana, India

Abstract: Soil-transmitted helminths [STH] are described as neglected tropical disorders (NTDS) since these impose terrific distress and disability, nevertheless, they can be eradicated or controlled. The pervasiveness of STH is more usual in rustic/bucolic areas than in city areas. STH signifies the worms present in the intestine provoking infection in humans and are transmitted/ conveyed *via* unhygienic/ dirty soil. “Helminth” denotes a parasitic worm and the causative agents/ chief species that can harm humans are the hookworms (*Ancylostomaduodenale* and *Necatoramericanus*), whipworms (*Trichuristrichiura*) and roundworms (*Ascarislumbricoides*). Various features namely, Hypersensitivity reaction (Type -1), the response of defective Th2, mucosal inflammation, volvulus, obstruction of small bowel and intussusception, blood loss in the mucosa, anaemia, *etc.* are involved in the pathophysiology of STH. To control mortality and morbidity, WHO has recommended population-based, specific, and target-based approaches. The medications recommended by WHO are Albendazole, Levamisole, Mebendazole, and Pyrantelpamoate as a single dose. Preclinical studies are being carried out on the ayurvedic and herbal treatments employing medicinal plants for STH infections as these are compatible with the body and have fewer side effects. The infection is now considered a major public health issue; the major role played by poor sanitation and hygiene in addition to this is certain environmental conditions. Thus, soil-conveyed helminth infections have a primary influence on socio-economic progress and advancement of society where occurrence rates are higher as such acquired infections influence the performance of adults to do work properly and provoke absenteeism amongst school-going children.

Keywords: *Ancylostomaduodenale*, *Ascarislumbricoides*, Adult parasitic worm, Cytokines, Anaemia, Anthelmintic, Deworming, Hypersensitivity reaction,

* Corresponding author Manish Dhall: College of Pharmacy, PGIMS (SDPGIPS), Pt. B. D. Sharma University of Health Sciences, Rohtak-124001, Haryana, India; Tel: +91-9315463343; E-mail: dhall_manish123@yahoo.co.in

Health education, Hookworm infection, Interlukin, IgE, Larvae, Lumbricoides, Mucosal inflammation, *Necatoramericanus*, Roundworm, Sanitation, STH, Soil transmitted Helminth, *Trichuristrichiura*, Th2 response, Unhygienic, Volvulus, Whipworm.

1. INTRODUCTION

Soil-transmitted helminths signify the worms present in the intestine provoking infection in humans and are transmitted/ conveyed *via* unhygienic/ dirty soil. Helminth infections passed on by the soil are the most prevalent illness, spread universally, and influence the most deprived and underprivileged population. These are conveyed by eggs existing in the faecal matter of humans, which in turn infect the soil present in moist and warm areas where hygiene and cleanliness are inadequate. Children infected by parasitic worms are generally deprived of micronutrients and exhibit physical or cognitive degeneration. The infection acquired by helminths is also common in pregnant women. It results in anemia and the possibility of carrying a newborn in pregnant women with lesser weight at the birth time [1]. About 1.5 billion humans or 24 percent of the population of the world acquire soil-conveyed helminth infections globally [2].

“Helminth” denotes a parasitic worm and the causative agents/ chief species that can harm humans are the hookworms (*Ancylostomaduodenale* and *Necatoramericanus*), roundworms (*Ascarislumbricoides*) and whipworm (*Trichuristrichiura*) [3]. The roundworm and whipworm largely affect children, while hookworm influences both children and youthful grown-ups. Soil-transmitted helminth species (STH) are usually categorized as a group since these require alike processes of diagnosis and act in response to a similar class of medicines. A parasitic worm in the intestine with specific features is *Strongyloides stercoralis* and this parasite needs distinctive procedures in comparison to other helminthiasis conveyed by soil and not normally identified [4].

Soil-transmitted helminths are also described as neglected tropical disorders (NTDS) since these impose terrific distress and disability; nevertheless, they can be eradicated or controlled. The pervasiveness of STH is more usual in rustic/bucolic areas than in city areas [5]. Helminth infections are extensively prevalent in the subtropical and tropical regions with utmost numbers happening in America, East Asia, sub-Saharan Africa, and China [6]. More than 267 million kids of the kindergarten age group and greater than 568 million children going to school reside in the premises where these parasitic worms are rigorously transmitted and such children are in great need of medication and precautionary interventions [7]. Nearly 576 to 740 million humans worldwide are acquiring infection with hookworm. About 807 to 1221 million humans in the world are prone to infection from *Ascaris*, a roundworm. Closely 604 to 795 million people

account for worldwide illness with whipworm [8].

STH illness is likely to instigate chronic disease silently. The worm burden is not evenly dispersed among the populace globally. Only a small number of humans bear a heavy load of worms, while most people harbor a smaller number of severe infections [9]. It is significant to determine the proportion of infected humans having a higher load of parasitic worms since they are more prone to disability risk. These intensely infected humans having higher worm loads are the chief source of infectivity in an environment and the spread of infection. Soil-conveyed helminth infections have a primary influence on socio-economic progress and advancement of society where occurrence rates are more as such acquired infections influence the performance of adults to do work properly and provoke absenteeism amongst school-going children [10].

2. CLINICAL FEATURES OF HELMINTHIASIS

The clinical features of soil-transmitted helminthiasis [STH] occurring through *Ascarislumbricoides*, *Trichuristrichiura*, *Ancylostomaduodenale*, and *Necatoramericanus* are summarized and represented in Fig. (1) [11 - 15].

2.1. Mode of Transmission of Helminth Infection

Helminths passed on into the soil are conveyed by the eggs that are transmitted in the faecal matter of humans having an infection with parasitic worms. The worms on attaining an adult stage thrive in the intestine where they get a favorable environment to generate thousands of eggs per day. If the human host acquires infection from worms defecates in public places (preferably near the plants in fields or garden premises) or if the faecal matter of an infected individual is employed as fertilizer, eggs are put down onto the soil. One gram of faecal matter from a human carrying an infection can hold up to 100 parasitic eggs. The soil in overcrowded areas lacking satisfactory cleanliness and hygiene gets contaminated by eggs [16]. This can occur by various means:

- Eggs of worms are ingested from unhygienic and polluted water sources;
- Eggs of worms get affixed to fruits and vegetables that are swallowed when the fruits and vegetables are not cautiously washed, cleaned, peeled, or properly cooked;
- Eggs of worms are consumed by kids playing in the infected soil and after that place their dirty fingers unknowingly in their mouths without cleaning and washing hands [17].

Additionally, the eggs of hookworms hatch in the soil, producing immature

Current Therapeutic Strategies for Neurocysticercosis and Leishmaniasis

Nitin Goel^{1,*}, Arvinder Kaur¹, Lalit Gupta¹, Rajiv Sharma², Satvinder Kaur², Vishnu Mittal³ and Vani Dawar³

¹ G.H.G. Khalsa College of Pharmacy, Gurusar Sadhar, Ludhiana, India

² University Institute of Pharma Science Chandigarh University, Gharuan, Mohali, India

³ Guru Gobind Singh College of Pharmacy, Yamunannagar, Haryana, India

Abstract: The most prevalent parasite condition affecting the brain, neurocysticercosis (NCC), is a well-known contributor to new seizures all over the world including India. The only prevalent cause of acquired epileptic seizures in underdeveloped nations, whereas active epilepsy is a common cause in affluent nations, that is cysticercosis, a parasitic ailment of the neurological structure in humans initiated by the larval stage of the tapeworm *Taenia solium*. The location of the cysticercus affects the pathogenesis, natural history, clinical symptoms, and therapy. For instance, the primary clinical signs and symptoms differ depending on the type of disease. Seizures or headaches are generally the first symptoms of parenchymal NCC. Leishmaniasis is brought on by parasites of the genus *Leishmania* in the *Trypanosomatidae* family which is among the most neglected tropical infectious diseases. Over 20 different *Leishmania* protozoa types can cause the complex vector-borne disorder leishmaniasis, which has a variety of clinical presentations ranging from localised skin ulcers (cutaneous leishmaniasis) to a systemic illness that can be fatal if left untreated (visceral leishmaniasis). There is not a single effective Leishmaniasis treatment available now for all species and symptoms. Furthermore, the present therapeutic approaches frequently do not lead to a parasitological cure and recurrence in the context of immunodeficiency (*i.e.*, HIV) is an emerging area that needs further research. So, this review is a discussion of a combination of all aspects related to Leishmaniasis, and how to use old treatment methods such as monotherapy along with modern strategies to combat this major health issue all over the world.

Keywords: Acquired epileptic seizures, Conventional drugs, Cutaneous leishmaniasis, Cysticercosis, Leishmaniasis, Mucocutaneous leishmaniasis, Neurocysticercosis (NCC), Neurocysticercosis (NCC), Neglected disease, Recent strategies, *Taenia solium*, Visceral leishmaniasis.

* Corresponding author Nitin Goel: G.H.G. Khalsa College of Pharmacy, Gurusar Sadhar, Ludhiana, India; E-mails: nitin.goel3077@gmail.com, arvinderpharma@gmail.com

1. INTRODUCTION

Cysticercosis, a parasitic disease of the nervous system in humans caused by the larval stage of the tapeworm *Taenia solium*, is the only common cause of acquired epileptic seizures in the developing world, where active epilepsy is a common cause in developed countries [1 - 3].

All over the world, including India, neurocysticercosis (NCC) is the most predominant parasite ailment affecting the brain and a common recognizable cause of new seizures. NCC was the cause of epilepsy (at least one seizure in the five years prior to the survey) in at least a third of the patients, in a community survey of more than 50,000 persons in the district of Tamil Nadu, southern India [4]. According to the findings of the survey, there are 1 in 1000 cases of active epilepsy in India that are caused by NCC. Therefore, NCC is the cause of active epilepsy in at least 1.2 million Indians [5]. Solitary cysticercus granuloma (SCG), initially discovered in 1989, is the most prevalent ailment in India, appearing in up to 60% of NCC patients [6, 7].

The pathogenesis, regular history, clinical signs, and executives differ in the area of the cysticercus [8]. For instance, the real clinical signs shift between various types of illness (Table 1). Parenchymal NCC regularly causes seizures or migraine. Ventricular NCC most frequently gives obstructive hydrocephalus. Subarachnoid NCC can offer hydrocephalus, meningitis, stroke, or central neurologic discoveries. Blended structures are likewise normal. Because of the intricacy of analysis and the board, the American Culture for Tropical Medication and Cleanliness (ASTMH) and the Irresistible Infections Society of America (IDSA) consented to mutually foster rules for the determination of NCC [9]. The Neurocysticercosis Classification and Neuroimaging According to Parasite's Location, Appearance with the Surrounding Host Tissue is shown in Table 1.

Table 1. Neurocysticercosis Classification and Neuroimaging According to Parasite's Location, Appearance with the Surrounding Host Tissue.

Form ¹	Characteristic on Neuroimaging	Histopathology
Parenchymal²		
Nonviable calcified	Nodular calcifications Size:<20 mm in diameter (often 1–5 mm). With or without context oedema.	Calcified granuloma. With or without context inflammation and/or gliosis.
Single, small enhancing	Cystic or nodular enhancing lesion. Size: <2 cm.	Single parenchymal parasites. With context inflammation. Variable opacification. Absence of the cyst fluid.

(Table 1) cont....

Form ¹	Characteristic on Neuroimaging	Histopathology
Viable parenchymal	Vesicular lesions. With evidence of associated contrast enhancement. High-definition imaging of scolex.	Parasites with intact cyst wall, vesicular fluid and scolex. With variable amounts of inflammation.
Extraparenchymal³		
Intraventricular	Cysticerci within the ventricles. Obstructive hydrocephalus or loculated hydrocephalus	Viable Cysticerci within the ventricles. Obstructive hydrocephalus
Subarachnoid	Cysticerci in the Sylvian fissure, in the basilar cisterns, or interhemispheric spaces. Strokes or meningitis without discrete cysts.	Cysticerci in the subarachnoid space mostly with arachnoiditis, and vasculitis. The cysticerci are in clusters with racemose May lack a scolex.
Spinal	Cysticerci within the spinal subarachnoid area. Intramedullary cysticerci within the spinal cord.	Subarachnoid cysticerci with attendant arachnoiditis. Intramedullary cysticerci analogous pathologically to parenchymal cysticerci.

Abbreviations: CT, computed tomography; MRI, magnetic resonance imaging.

¹With the exception of single enhancing lesions that are also viable, which are classed with single enhancing lesions, patients with more than one form are classified according to the form found lower on the chart. Ocular cysticercosis is separately classified.

²Refers to cysticerci in the parenchyma of the brain. Small cysticerci that are present in the gyri above the cerebral convexity respond clinically similarly to parenchymal cysticerci and are categorized with them. Large parenchymal cysticerci (>20 mm) and several inflammatory parenchymal cysticerci with diffuse cerebral edema are rare types of neurocysticercosis.

³Refers to cysticerci outside of the brain parenchyma in the central nervous system.

2. THE PARASITE

Taenia solium is a dichotomous zoonotic cestode. The grown-up stage is a 2-4 m long tapeworm that lives in the small digestive tract of people. In nature, *T. solium* tapeworms have no other known end hosts. Likewise, with all cestodes, the gravid proglottids at the terminal end of the worm are loaded up with eggs, which are the wellspring of larval contamination or cysticercosis. The normal transitional host is the pig, which conceals larval blisters in any piece of its body. People become contaminated with blisters through unintentional ingestion of infective *T. solium* eggs through waste oral defilement (Fig. 1).

Current Therapeutic Strategies for Buruli Ulcer

Manisha Bhatia¹, Jasmine Chaudhary^{1,*}, Akash Jain¹ and Ashwani Dhingra²

¹ M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala-133207, Haryana, India

² Guru Gobind Singh College of Pharmacy, Yamunanagar, Haryana, India

Abstract: The skin is a multifaceted organ with varied functions, but its exposure to various environmental conditions, including exposure to ultraviolet light, trauma, and infections, makes it more prone to ulcers. Ageing, poor lifestyle, and certain diseases, like obesity, hypertension, diabetes, *etc.*, further exaggerate the cause. Skin ulcers are wounds (sores) often caused by reduced blood flow leading to absolute loss of the epidermal layer along with parts of the dermis or subcutaneous fat, and thus have tremendously slow healing affinity. Buruli ulcer (BU), or Bairnsdale is a type of necrotizing skin ulcer mainly caused by the bacterium, *Mycobacterium ulcerans*, and characterized initially by the formation of papules or nodules (edematous lesions), which further progresses to chronic skin ulceration as a result of epidermal hyperplasia, collagen destruction, and vascular damage in the underlying dermis and subcutis. It is considered one of the 20 neglected diseases of the skin by the World Health Organization (WHO). Although scattered in more than 33 countries, its prevalence is the highest in West Africa and this incidence has risen manifold during the last few years, which might be due to deforestation, artificial topographic alterations, and increased manual agriculture. Mycolactone, a polyketide-based immunosuppressive macrolide, is considered the major factor responsible for the pathogenesis of the disease. Its high toxicity dampens the immune system, causing extensive tissue destruction mainly in skin cells and minute blood vessels, leading to ulceration and skin loss. Generally, a combination of rifampicin with streptomycin, amikacin, clarithromycin, or ciprofloxacin along with oral prednisolone for eight weeks is specified as a first-line treatment. Surgery to remove necrotic tissue, BCG vaccination for short-term protection, and physiotherapy to promote healing are also found beneficial. To combat this deadly disease, enhanced public education and awareness through outreach initiatives is a must as prevention is always considered better than cure. Further studies in this area may be helpful in investigating more treatment regimens along with various ways by which the occurrence of Buruli ulcer can be avoided. The present study is therefore designed to compile all relevant literature, which can serve as an important lead for further investigations in this area of research.

Keywords: Antibiotics, Buruli ulcer, *Mycobacterium ulcerans*, Skin ulcer.

* Corresponding author Jasmine Chaudhary: M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala-133207, Haryana, India; E-mail: jasmine.jain@mmumullana.org

1. INTRODUCTION

The skin is the most external part of the human body [1], comprising an intricate, complex network that is meant to defend our body from the direct attack of foreign particles, harmful rays, radiations, or entry of any kind of detrimental incursion. The skin tends to keep the human body safe and secure from the attack of injurious substances, pathogens, UV light, chemicals, and mechanical injury [2]. It consists of many layers that have a different moderately acting role to perform. Apart from safety, it performs miscellaneous functions that include excretion, defense mechanism, different climates, variations in extremes of temperature range, and protection. Being a complex organ, it is continuously exposed to environmental elements, the most important being ultraviolet light, trauma, and infections [3]. The skin is quite susceptible to disorders and diseases, especially microbial infections, which include cellulitis, erysipelas, impetigo, folliculitis, furuncles and, carbuncles and many more [4]. In substantial cases, it can also be affected due to the administration of some allergic food or, creams or any other product and gets infected. Skin infections are considered the 28th most common diagnosis in hospitalized patients [5]. Skin diseases are actually very hazardous as it imparts a lot of pain, tenderness, inflammation, redness, swelling and soreness to the patient. Most of these skin diseases have already been claimed, and understood, and required medicines are prepared to cure the particular disease. But the irony is that despite being common, they are not considered a noteworthy problem due to the myth that these are benign, not very critical, can cause minor nuisance, and ultimately are not fatal or life-threatening.

2. ULCERS

Ulcer can be clearly understood as a wound in which the epidermal skin layer is completely lost, affecting the surface tissue causing disintegration of the epithelial layer with eroded mucosa and extremely slow healing tendency. The incidence and intensity of ulceration is on a great rise due to varying factors such as stress, psychosocial conditions, age, alcohol consumption, population density, smoking, obesity, and diabetes, which at the same time elevates the risk factors for atherosclerotic occlusion [6]. Skin ulcers generally develop due to poor circulation, metabolic disorders, and bacterial infections, representing a difficult clinical problem and a major public health concern. Persistent wounds and ulcers affect more than 1% of the population with diverse etiologies, and their prevalence is estimated to rise significantly in the upcoming years [7]. Superficial skin ulcers may herald a primary disease ranging from acute to chronic, turning into malignant [8]. Ulcer changes further into acute wounds or *vice-versa* by proper treatment, thereby removing its underlying etiology and ultimately reversing its chronic nature [9]. Skin ulcer leads to a deep depression with a raised

and inflamed outer border, with the surrounding skin showing discoloration, turning black as the tissue dies. Skin ulcer initiates slowly and gradually worsens giving a burning or itching sensation, disintegrating the skin tissue, and eroding away.

2.1. Types of Ulcers

Ulcers can be classified into the following four types:

2.1.1. Decubitus Ulcers

Decubitus ulcers, popularly known as pressure ulcers, pressure injuries, or bedsores, are localised skin and soft tissue injuries causing damage to the underlying tissue. They generally occur as a result of constant pressure exerted on the skin for a prolonged period of time, decreasing the blood flow to the affected area, which can be fatal, leading to tissue damage. This class of ulcer tends to affect bony areas of the body, which are vulnerable to friction. The parts of the body more susceptible to this category of pressure ulcers include the back, tailbone, elbows, ankles, ischium, trochanter, sacrum, heel, malleolus and occiput [10].

2.1.2. Venous Ulceration

Venous ulceration, also termed varicose ulcer and stasis ulcer, is the most devastating effect of chronic venous disorders, resulting in more than 80 percent of lower extremity ulcerations with reduced mobility and financial constraints [11]. There are multiple reasons responsible for causing venous ulcers, such as poor blood circulation in the lower extremities, such as legs, varicose veins, obesity, trauma, age factor, sedentary lifestyle, lack of movement, and pregnancy, which can be contributing factors for the development of these ulcers.

2.1.3. Arterial Ulcers

Arterial ulcers, arterial wounds, or ischemic ulcers typically occur due to poor delivery of nutrient-rich arterial blood to the lower extremities, such as legs, ankles, and feet. Due to this poor perfusion, there is a depletion of oxygen content in the overlying skin and tissues, killing them and eventually turning them into an open type of lesion. The inadequate delivery of blood consequently leads to minor cuts, which do not cure easily, eventually causing necrosis, tissue damage, ulcer formation, and infection. Atherosclerotic disease is the major contributing factor apart from diabetes, vasculitis, gangrene, thalassaemia, and sickle cell disease.

Current Therapeutic Strategies for Trachoma

Himani Bajaj¹, Sindhu Agarwal^{1,*}, Anjali Sharma², Mayank Yadav¹ and Md. Arif Naseer¹

¹ AVIPS, Shobhit University, Gangoh, Saharanpur, UP, India

² Guru Gobind Singh College of Pharmacy, Yamunanagar, Haryana, India

Abstract: As a result of persistent follicular conjunctivitis brought on by *Chlamydia trachomatis* and consequent corneal scarring, about 6 million people have irreparable blindness. *Chlamydia trachomatis* is a bacterium that causes trachoma, an eye infection. Early signs include eyelid itchiness and irritation, whereas advanced signs include swollen eyelids, pus oozing from the eyes, photophobia (light sensitivity), discomfort in the eye, and vision issues. Using the SAFE strategy, the WHO is driving an international campaign to eradicate Blinding Trachoma. Trichiasis surgery, antibiotic treatment for infection, hygiene promotion on the face, and environmental changes to improve air quality are all part of this. The best antibacterial medication for widespread distribution is oral azithromycin.

Keywords: Antibiotics, Eyelids, Hygiene, Trachoma, Vaccine.

1. INTRODUCTION

Trachoma (truh-KOH-muh), which is caused by specific *Chlamydia trachomatis* serovars [1 - 3], is the most prevalent blindness caused by infection [4]. An infection-related inflammatory conjunctivitis is known as “active trachoma.” [5, 6]. Repeated bouts [7 - 9] of active trachoma scarring on the eyelids may cause trachomatous trichiasis (TT), in which one or more eyelashes are redirected to touch the eye. The discomfort from TT is terrible [10 - 15]. It can be fixed with surgery. If left untreated, it may cause corneal opacification, blurred vision, and blindness.

Your eyes are impacted by trachoma. *Chlamydia trachomatis* bacteria is the cause of it. Trachoma can be disseminated through direct contact with an infected person's eyes, eyelids, nose, or throat secretions. Handling contaminated objects, including handkerchiefs, has the potential to spread the disease [16 - 18].

* Corresponding author Sindhu Agarwal: AVIPS, Shobhit University, Gangoh, Saharanpur, UP, India; E-mail: agarwalsindhu8@gmail.com

The eyes and eyelids may first feel mildly uncomfortable and irritated due to trachoma. Then, your eyelids can swell and start to drain pus (Fig. 1). Blindness may develop from trachoma if it is not treated [19].




Fig. (1). Progression of trachoma [20].

The most commonly diagnosed form of blindness in the world is trachoma. Eight five% of trachoma cases happen in undeveloped areas of Africa, where the disease is very prevalent. In areas where the disease is prevalent, trachoma infection may be present in 60% or more of children under the age of five.

Trachoma problems may be avoided with early treatment [19].

2. CHLAMYDIA TRACHOMATIS

It is a gram-negative, intracellular, obligatory *Chlamydia trachomatis* bacteria. Its only known natural host is humans [15]. The most prevalent bacterial lymphatic system infections (serovars A–C) and sexually transmitted infections (STIs) in the globe are caused by several chlamydial serovars. (serovars L1 to L3) [18].

2.1. Symptoms and Signs

Trachoma often affects both eyes and signs and symptoms may include:

- Mild eye itching and irritation;
- Mucus- or pus-filled eye exudate;

- Swollen eyelid;
- Photophobia;
- A headache;
- Crimpsoneye; and
- Loss of vision.

Infection is particularly prone to affect young children. However, the illness advances gradually, and the more agonising symptoms cannot show up until adulthood [21].

2.2. Stages of Trachoma

According to the World Health Organization (WHO), trachoma develops in five stages [5]:

2.2.1. Follicular Inflammation

When seen under a magnifying glass, the inner surface of your upper eyelid will reveal five or more follicles, which are tiny bumps containing lymphocytes, a kind of white blood cell, in the early illness (conjunctiva).

2.2.2. Severe Inflammation

The top eyelid may thicken or enlarge at this point, and your eye is now highly contagious and inflamed.

2.2.2.1. Scarring on the Eyelids

Recurrent infections cause scarring on the inner eyelid. The scars typically appear as white lines when magnified. You could develop a malformed, inward-slanting eyelid (entropion).

2.2.3. Twisted Eyelashes (trichiasis)

Your eyelashes curl inward and rub against the transparent outside of your eye as a result of the distorted inner lining of your eyelid (cornea).

2.2.4. Cloudy Cornea (Opacity)

An inflammation that most frequently appears under your top lid affects the cornea. The cornea becomes clouded as a result of ongoing inflammation that is aggravated by scratching from the in-turned lashes.

Your upper lid exhibits all trachoma symptoms more severely than your lower lid. A disease process that starts in childhood can carry over into adulthood if no action is taken.

Current Therapeutic Strategies for Food Borne Trematodiasis

Nidhi Gupta^{1,*}, Inderjeet Verma¹ and Hasandeep Singh²

¹ M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala-133207, Haryana, India

² Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab-143005, India

Abstract: Food-borne trematodiasis are among the neglected tropical diseases caused due to liver flukes (*Clonorchis sinensis*, *Fasciolagigantica*, *Opisthorchis viverrini*), lung flukes (*Paragonimus* spp.) and intestinal parasitic flukes (*Echinostoma* spp.) infections and is an emerging public health problem. They are mostly found in developing countries and in areas where they are present, they aggravate poverty. However, they are no longer being neglected because of their broad geographical distribution, a wide range of infected people, and measures available to control several neglected tropical diseases. WHO estimates that every year two million people are suffering from disability and death due to these neglected diseases. The treatment of food-borne trematodiasis, a neglected disease, is important for preventing the progression of clinical diseases and reducing the associated morbidity. In the present chapter, we will discuss the food-borne trematodes' life cycle, associated symptoms, diagnosis and various strategies used in treating food-borne trematodiasis. Currently used chemotherapeutic drugs, their safety, therapeutic profile, and resistance developed are summarized here. Furthermore, emphasis is given to developing a broad-spectrum trematocidal drug with high safety and efficacy.

Keywords: Artesunate, Artemether, Chemotherapy, Diagnosis, Food-borne trematodiasis, Geographic distribution, Lifecycle, Mefloquine, Praziquantel, Symptoms, Therapeutic strategies, Triclabendazole, Tribendimidine.

1. INTRODUCTION

Food-borne trematodiasis are one of the neglected tropical diseases caused by intestinal, lung, and liver parasitic fluke infections. The parasites included are *Clonorchis*, *Fasciola*, *Paragonimus*, and *Opisthorchis* [1]. The life cycle of these parasitic flukes is known to be complex because of their presence in different

* Corresponding author Nidhi Gupta: M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala-133207, Haryana, India; E-mail: gupta21nidhi@gmail.com

definitive hosts or one or two intermediate hosts. In humans, infection due to food-borne trematodiasis spreads by eating contaminated food. The infection produces various lung and liver diseases and every year, two million people suffer from disability and death worldwide due to these diseases [2].

The first food-borne trematode was discovered in 1760 in Germany during the postmortem examination of a female body. Then it was found to be a parasitic worm that belongs to the genus *Fasciola* [3]. The *Clonorchis sinensis* infection was first time reported in 1874 during the postmortem examination of a 20-year-old Chinese woman that showed oozing out of small size, dark coloured vermicular-looking bodies from the bile duct. In 1879 and 1892, the first report of *Paragonimus sp.* and *Opisthorchis felineus* infection appeared, respectively [4]. After these discoveries, more than hundreds of food-borne trematodes have been isolated and identified that are present in humans and affect domestic animals. Lung and liver fluke organisms pose more problems in people compared to intestinal flukes [5]. Foodborne trematodiasis are endemic in various places in the world, particularly in rural places among low-wage earners, school children, and women of child-bearing age. In spite of changes in eating habits, health education, environmental alteration, industrialization, and the use of broad-spectrum antihelmintics, this disease is among the major public health problems [6]. In this chapter, the life cycle of food-borne trematodes, their geographical distribution, symptoms, diagnosis, and different treatment strategies for food-borne trematodiasis have been described.

2. THE LIFE CYCLE OF FOOD-BORNE TREMATODES

Food-borne trematodes can be found in each organ of their definitive hosts and have complex life cycles that also involve different larval types. The complete life cycle of food-borne trematodes is described in Fig. (1). Their life cycle includes different hosts including vertebrate definitive hosts, humans, an invertebrate, the first intermediate host (mollusk), and the second intermediate host having an encysted metacercarial stage. In humans or domestic animals, following sexual reproduction, eggs are produced and released *via* feces or sputum [7].

Eggs of the parasites from infected humans or animals reach the freshwater bodies *via* contaminated feces. This may occur due to the defecating habits of humans in an unhygienic manner or the human feces used as fertilizer. These food-borne trematodes are mainly present in animals such as cats, dogs, foxes, rodents, and pigs, which are the definitive hosts for *C. sinensis*, whereas *F. hepatica* are mainly present in domestic ruminants. Once the eggs reach fresh water, their development occurs and miracidium is released that enters into the aquatic snail known as the first intermediate host. After several weeks, the development of

miracidium into cercariae takes place. They are then released into the freshwater environment, attach, penetrate, and encyst in the form of metacercariae in the second intermediate host. By ingesting metacercariae, food-borne trematode infection is achieved through eating raw fish, freshwater crabs, and aquatic plants or by drinking contaminated water [8].




Fig. (1). Life cycle of food-borne trematodes.

3. GEOGRAPHIC DISTRIBUTION

The food-borne trematodiasis transmission is restricted to those areas where the first and second intermediate hosts present together under conditions requiring appropriate environmental factors and where humans usually eat raw, undercooked fish and similar aquatic products [8, 9]. The number of infectious cases varies according to the trematode species. Worldwide, more than 200 million people were found to be at risk of *C. sinensis* infection, more than 15 million have been infected, and over 1.5 to 2 million showed complications. China has the maximum number of *C. sinensis* infected people, that is, around 13 million [10]. Around 20 million people have been found to be infected with *Paragonimus sp.* and 293 million people are at risk [11]. With *Opisthorchis viverrini*, 10 million people are infected [12] and with *Fasciola sp.* between 2.6 to 17 million people are found to be infected globally [13]. Approximately 3.5 billion people are found to be infected with different species of intestinal flukes [14].

4. SYMPTOMS

According to WHO, the public health burden due to food-borne trematodiasis is because of morbidity rather than mortality because most of the early and light infections mostly go unnoticed. In case of chronic infections, severe morbidity

SUBJECT INDEX

A

Acids, nucleic 206
 Action 53, 98
 anticholinesterase 98
 antiviral 53
 Activities 40, 58, 61, 152, 208
 anti-HIV 58
 anti-viral 61
 antibacterial 40
 antimalarial 208
 metabolic 152
 Albendazole therapy 122
 Allergy reactions 70
 Amazonensis 130, 131, 136, 137, 138, 154
 Amphotericin 139, 140, 141, 144, 145, 149, 151, 152
 liposomal 141, 145
 Amplification 39, 119
 biotin-streptavidin signal 39
 AMR surveillance in leprosy 41
 Antenatal anthelmintic treatment 99
 Anthelmintic activity 100, 102
 Anti-inflammatory medications 5, 54
 Antibiotics, aminoglycoside 142
 Antiepileptic medications 120, 123
 Antiparasitic 122, 123, 124, 125, 126, 127, 208
 agent 208
 drug treatment 124
 medications 122, 123, 124, 125, 126, 127
 treatment 124, 127
 Apoptosis 143, 172, 189
 stress-induced 189
 Apoptotic signalling pathways 189
 Atherosclerotic disease 168

B

Bacteria 33, 35, 143, 146, 151, 170, 171, 186, 189, 206
 chlamydial 186

Bacterial 38, 69
 infection, crucial 69
 intensity (BI) 38
 Bacterial infections 69, 70, 167
 secondary 69
 Blood, nutrient-rich arterial 168
 Broad-spectrum antihelmintics 201
 Bronchoscopy 95

C

Cardiovascular diseases 2, 59
 Chaulmoogra oil 39
 Chikungunya 4, 10
 Chlamydia 185, 189, 192
 trachomatis infection 192
 infections 185, 189
 Cholangiocarcinoma 203
 Control of neglected tropical diseases 3, 18, 22
 Coronary heart disease (CHD) 185
 Corticosteroids 5, 56, 120, 123, 124, 125, 127
 Cryotherapy 145
Cucuma longa 101
 Cutaneous leishmaniasis 6, 112, 128, 129, 135, 140, 145, 147
 skin lesions 6
 Cycles, disease-poverty-disease 81
 Cysticercosis 112, 113, 114, 128
 Cytokines, immunostimulatory 149

D

Dendritic cells 53
 Dengue virus 48, 51, 53, 54, 59, 62
 genetics 62
 infections 48, 51
 DENV, transmit 53
 Diabetes mellitus 2, 141
 Diarrhea 54, 79, 102
 Disability 18, 41, 75, 91, 92, 200, 201
 lifelong 75

Diseases 2, 6, 7, 8, 11, 17, 19, 25, 26, 32, 33, 41, 49, 75, 82, 95, 113, 148, 166, 169, 170, 172, 183, 185, 201, 210

arterial 169

endemic 17

etiopathogenesis 49

inflammatory 169

lepromatous 33

liver 201

parasitic 26, 75, 113

Disorders 2, 33, 38, 128, 130, 153, 167

autoimmune 33

dermatological 38

metabolic 167

non-communicable 2

DNA 40, 59, 82, 119, 141, 155, 170, 206

enzymes 206

gyrase 40

replication 40

topoisomerase 141

vaccine's nano-delivery system 82

viral 59

Doxycycline treatment 7

Dracunculiasis 3, 9, 11, 23, 66, 75, 78, 81, 82
parasite disease 66

Dracunculus infects snakes 76

Drugs 20, 21, 97, 98, 99, 100, 101, 125, 127, 140, 141, 144, 145, 151, 152, 200, 209, 210, 211

anti-inflammatory 125, 127

anti-leishmanial 140

antimonial 141

antiparasitic 125

chemotherapeutic 200, 209

Dysfunction 40, 69

lymphatic 69

Dyspepsia 203

E

Elephantiasis 66, 67, 69

Enzyme-linked immunosorbent assays 72, 206

Eye(s) 9, 183

infected 9

itching 183

F

Fever 5, 35, 48, 52, 77, 172, 203, 207

acute-onset high 48

hemorrhagic 48

Filariasis test strip (FTS) 72

Flaccid paralysis 98

FLOTAC technique 205

Functional *de novo* purine manufacturing pathways 121

G

Global 22, 23, 41, 82

health assembly 82

impact of neglected tropical diseases 22

leprosy strategy 41

NTD control 23

Globalisation 62

Glucose metabolism 142

Glycogen stores 98, 122

Glycolysis 188

aerobic 188

Glycoproteins 60

H

HCV proteases 58

Healing, cutaneous lesions 146

Helminth endoparasite infections 82

Helminth Infection 7, 92, 93, 102, 103, 209
soil-transmitted 7, 103

Helminthiasis 7, 92, 97, 103, 104

transmitted 97, 103, 104

Helminthiasis 93, 94

Helminthic disease 66, 101, 205

Hepatica infection 208

HMG-CoA reductase inhibitors 59

Hookworm infestation 99

Host-viral interaction 51

Hygiene 16, 18, 19, 91, 92, 93, 102, 103, 104, 182, 185, 193, 194

Hypergammaglobulinemia 137

Hypersensitivity 91, 95, 96, 121

reaction 91, 95, 96

symptoms 121

Hypoglycaemia 141

Hypokalemia 144

Hypotension 144

Subject Index

Emerging Approaches to Tackle Neglected Diseases 217

I

Immune response systems 155
Immunochromatographic card test (ICT) 71, 72
Immunodiagnostic techniques 205
Immunological reaction 39, 70, 80, 205
Infect macrophages 134, 189
Infection 1, 16, 18, 53, 66, 67, 68, 69, 83, 92, 93, 94, 97, 98, 103, 104, 143, 146, 155, 170, 182, 185, 186, 190, 201, 205
 amazonensis 143
 asymptomatic 155
 fungal 69
 lung 146
 parasite 1, 16
 related inflammatory conjunctivitis 182
 soil-transmitted 103
Infection transmission 185
Inflammatory 125, 127, 171, 172, 189
 reaction 189
 responses 125, 127, 171, 172
Inhibitors 58, 59, 61, 119, 142, 186, 206
 enzyme 119
 glycosidase 59
Interventions 8, 19, 21, 22, 98, 99, 104, 186, 210, 211
 agricultural 210
 population-based 98
 traditional therapeutic 186

L

Leishmania 129, 130, 133, 134, 136, 141, 143, 145, 146, 149, 151, 152, 155
 disease 149
 donovani in macrophages 151
 lesions 145
 parasites 143, 146, 149, 152
 therapy 149
Leishmaniasis 6, 17, 112, 128, 129, 131, 132, 134, 137, 138, 145, 146, 150, 151, 152
 disorder 112
 mucus 6
Leishmaniasis disease 134
Leprosy 10, 22, 23, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42
 infection 32
 infectious disease 10

Lesions 33, 35, 36, 37, 38, 79, 80, 81, 117, 120, 131, 132, 135, 136, 137, 138, 147, 166, 171, 172, 175, 180
 anesthetic skin 38
 brain 117, 120
 cutaneous 136
 edematous 166
 lepromatous 38
 metastatic 117
 nasal mucosal 33
 painful 175
 peptic ulcer 80
Liposomes 6, 150, 151
Lumricoides 95
Lung 70, 95, 206
 biopsy 95
 fluke infections 206
Lymphangiectasis 70
Lymphatic system 66, 67
Lymphedema 67, 69
Lymphoedema 69, 172

M

Magnetic resonance imaging (MRI) 95, 114, 116, 117, 120, 204
Malignancies, cutaneous 141
Malnutrition 99
MAP kinase signaling 34
Medications 6, 7, 10, 11, 19, 20, 39, 59, 61, 91, 103, 119, 122, 124, 139, 148, 149, 150, 151, 192
 anti-helminth 61
 anti-leishmanial 151
 antileishmanial 148, 150
 immunosuppressive 59
Medicines 26, 58, 60, 73, 92, 99, 103, 140, 143, 147, 149, 153
 antileishmanial 149
 antimonial 140
 antiviral 60
 herbal 99
 synthetic immunostimulatory 149
Metabolism 99, 188
 protein 99
Metabolites 188
Metal-based nanoparticle systems 151
Methods 41, 150
 therapeutic 41
 traditional drug delivery 150

Microbial infections 167
Microbiota, intestinal 95
Microsurgical cystectomy 126
Monstrous cysticercosis disease 116
Montenegro skin test 132
MRI 118
 techniques 118
 technology 118
Multi-drug therapy (MDT) 30, 31, 39, 40, 41, 148

N

Nasal continuous positive airway pressure (NCPAP) 56
National institute of communicable diseases (NICD) 78
Nausea 52, 79, 142, 207
Nerve sensation 35
Nested PCR methodology 119
Neurocysticercosis, parenchymal 115
Neuroendoscopy 126
 invasive 126
Neuropathy, peripheral 31
Nutritional effects 94

O

Onchocerciasis transmission 22
Opisthorchis felinus infection 201

P

Pain, chest 204
Pancreatitis 95, 141, 144
Pancytopenia 137
Paragonimiasis 207, 210
Parasite 127, 153
 diseases exacerbates inflammation 127
 proteins 153
Parenchymal cysticerci, inflammatory 114
PCR-based techniques 119
Photodynamic therapy 155
Polymeric nanoparticles and liposomes 150
Preventative chemotherapy 2, 19
Pro-survival signalling pathways 189
Progress 6, 21, 22, 39, 75, 81, 172, 174
 economic 81
Proinflammatory 71

Promastigotes 131, 133, 134, 146, 154
Proteins 34, 58, 70, 94, 98, 128, 140, 149, 153
 crucial 58
 microtubular 98
Public health hazards 22

R

Real-time polymerase chain reaction (RT-PCR) 38
Response 51, 60, 69, 94, 95, 129, 171, 172, 189
 immune 51, 60, 69, 95, 171, 172
 immunological 129, 189
 nutritional 94
Rifampicin 10, 30, 39, 40, 41, 166, 174, 177
 resistance 41
RNA 58, 59, 61
 dependant RNA polymerase 58
 inhibitor 59
 interference 61

S

Schistosomiasis 2, 3, 8, 11, 16, 18, 20, 23, 104
Schwann cells and macrophages 33, 34
Sensation 75, 77, 79, 168
 burning 75, 77, 79
 itching 168
Sensory mononeuritis 33
Serum antibody detection 132
Severe dengue disease 48
Sexually transmitted infections (STIs) 183
Shock 55
 hypovolemic 55
 syndrome 55
Single 32, 112
 effective Leishmaniasis treatment 112
 nucleotide polymorphism (SNPs) 32
Skin 7, 38, 121, 144, 166, 167, 168, 171, 176
 biopsy 38
 diseases 167
 infections 121, 167
 irritation 144
 rashes 7
 ulcer 166, 167, 168, 171
 ulceration 176
Snail habitat treatment 8

Subject Index

Soil-transmitted 1, 3, 7, 18, 20, 91, 93, 95, 97,
99, 101, 102, 103, 104
helminthiasis 3, 7, 18, 20, 91, 93, 95, 97,
99, 101, 102, 103, 104
helminthic infections 1
Stroke disorders 116
Surgical efforts 191
Syndrome 60, 138
acute respiratory 60
Synthesis, protein 143
Systems 67, 115, 133, 169
cutaneous vascular 169
focal sensory 115
gastrointestinal 133
immunological defense 67

T

Taenia infection 117
Target cell infection 62
Techniques 39, 94, 95, 119, 132, 146, 149,
153, 168, 172, 191, 193, 204, 205, 206
computational 153
immunological 204
serological identification 132
Thalassaemia 168
Therapeutic 60, 146, 154
activity 154
electricity 146
targets 60
Therapy 3, 6, 11, 17, 39, 40, 122, 123, 124,
126, 127, 139, 140, 141, 144, 146, 148,
174, 175
antibiotic 174, 175
anticysticercal 127
antiepileptic 123, 124
antimony 141
antiparasitic 122, 123, 124, 127
medicinal 126
Thermoregulatory 51
Thermotherapy technology 146
Throat, sore 52
Thrombocytopenia 52, 54, 56
Tissue 166, 176, 204
destruction 166
harmonic imaging 204
necrosis 176
Toxic effects 139
Toxin 171, 172
mycolactone 172

Emerging Approaches to Tackle Neglected Diseases 219

necrotic 171
necrotizing 171
Trachoma 183, 189
infection 183
problems 183
treating 189
Trachomatis 186, 187, 188, 189
bacteria transform 186
Trachomatous trichiasis (TT) 30, 35, 37, 182
Transferring technology 54
Treatment 104, 127, 141, 182, 194
anti-inflammatory 127
antibiotic 182, 194
antimony 141
herbal 104
Trematodiasis 202, 207
infection 207
transmission 202
Tuberculosis 16, 17, 169, 208

U

Ulcers 135, 138, 146, 166, 167, 168, 169, 171,
172, 173, 175, 176
diabetic foot 169
intractable 146
nasal mucosa 138
necrotic 176
neuropathic 169

V

Vaccinations 9, 39, 71, 81, 82, 127, 155
antirabies 9
Vacuoles, endocytic 187
Vascular system fullness 55
Vector control 22, 49
measures 22
techniques 49
Village level operation and maintenance
(VLOM) 193
Virus infections 48
Visceral leishmaniasis 6, 112, 128, 129, 131,
132, 137, 140, 141, 144, 145, 148, 149
Vomiting 52, 79, 142, 144, 207

W

Worms, ectoparasites 8



Prerna Sharma

Ms. Prerna Sharma currently serves as an assistant professor at Shri Krishna Ayush University, Kurukshetra. With 11.8 years of teaching experience, her expertise lies in the standardization of herbal plants and formulations. Her research focuses on pharmacognostical and phytochemical investigation of Indian medicinal plants. She has to her credit 50 research and review publications in reputable national and international journals, along with 40 copyrights, 2 patents, and participation in over 30 national and international conferences and workshops. Ms. Sharma has been honored with the Young Research Scientist Award by SPER and TIPA in Thailand.



Sumeet Gupta

Dr. Sumeet Gupta works as the Dean and Principal at M. M. College of Pharmacy, M. M. (Deemed to be University), Mullana, Ambala, Haryana. His main research interests include the scientific validation of plant-based compounds in the treatment of metabolic disorders and associated complications. With more than 22 years of teaching and research experience in the area of Preclinical and Clinical Pharmacology, he has published various research and review articles. Additionally, he has authored 4 books and contributed 6 chapters with international publishers. Dr. Gupta has been awarded 5 patents and 2 copyrights.



Hitesh Malhotra

Mr. Hitesh Malhotra currently serves as an Assistant Professor at Guru Gobind Singh College of Pharmacy, Yamuna Nagar. With 9 years of experience in this role, he specializes in animal experimentation. His research focuses on ethnopharmacology, as well as the isolation and characterization of phytochemicals. He has supervised approximately 15 master's students and has published over 20 research, review, and book chapters in both national and international journals. Additionally, he holds 2 patents and has participated in more than 50 conferences, workshops, and Faculty Development Programs (FDPs).



Bhawna Chopra

Dr. Bhawna Chopra, a distinguished academic and researcher in Pharmaceutical Sciences, focuses on the therapeutic potential of natural compounds. She holds a Bachelor's degree in Pharmacy from Guru Gobind Singh College of Pharmacy and a Master's degree from ISF College of Pharmacy. Her Ph.D. is from IK Gujral Punjab Technical University. With over 15 years of teaching experience, she received the Women Pharma Personality Award at the National Pharma Summit 2022. She is recognized as a Highly Cited Researcher by Elsevier and serves on editorial boards, including Bentham Science Publishers. She is an active member of professional organizations such as APTI, ISTE, and SPER, with over 85 publications, patents, and copyrights.



Sunil Sharma

Dr. Sunil Sharma is a Professor in the Department of Pharmaceutical Sciences at Guru Jambheshwar University of Science & Technology, Hisar. He earned his Bachelor's degree from B N College of Pharmacy, Udaipur, affiliated with Rajasthan University, Jaipur, in 1994. He completed his Master's degree in Pharmacy with a specialization in Pharmacology from L M College of Pharmacy, Gujarat University, Ahmedabad, in 1996. He obtained his Ph.D. from Guru Jambheshwar University of Science and Technology, Hisar. With 25 years of experience in academics, he has published 96 research papers in peer-reviewed journals of repute.